Seminars in Radiation Oncology
Volume 20, Issue 4 , Pages 267-273.e3 , October 2010

Enhancing Radiotherapy Through a Greater Understanding of Homologous Recombination

References 

  1. Ward JF. The yield of DNA double-Strand breaks produced intracellularly by ionizing-radiation—A review. Int J Radiat Biol. 1990;57:1141–1150
  2. Powell SN, Kachnic LA. Therapeutic exploitation of tumor cell defects in homologous recombination. Anti Cancer Agents Med Chem. 2008;8:448–460
  3. Filippo JS, Sung P, Klein H. Mechanism of eukaryotic homologous recombination. Annu Review Biochem. 2008;77:229–257
  4. Szostak JW, Orr-Weaver TL, Rothstein RJ, et al. The double-strand-break repair model for recombination. Cell. 1983;33:25–35
  5. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–921
  6. Willers H, Dahm-Daphi J, Powell SN. Repair of radiation damage to DNA. Br J Cancer. 2004;90:1297–1301
  7. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–917
  8. Foulkes WD. Molecular origins of cancer: Inherited susceptibility to common cancers. N Engl J Med. 2008;359:2143–2153
  9. Hiel JA, Weemaes CM, van den Heuvel LP, et al. Nijmegen breakage syndrome. Arch Dis Child. 2000;82:400–406
  10. Miyagawa K. Clinical relevance of the homologous recombination machinery in cancer therapy. Cancer Sci. 2008;99:187–194
  11. Li D, Liu H, Jiao L, et al. Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival. Cancer Res. 2006;66:3323–3330
  12. Li D, Frazier M, Evans DB, et al. Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol. 2006;24:1720–1728
  13. Barnett GC, West CML, Dunning AM, et al. Normal tissue reactions to radiotherapy: Towards tailoring treatment dose by genotype. Nat Rev Cancer. 2009;9:134–142
  14. Liu SK, Olive PL, Bristow RG. Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials. Cancer Metastasis Rev. 2008;27:445–458
  15. Soderlund K, Skoog L, Fornander T, et al. The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer. Radiother Oncol. 2007;84:242–251
  16. Soderlund K, Stal O, Skoog L, et al. Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer. Int J Radiat Oncol Biol Phys. 2007;68:50–58
  17. Yang MH, Chiang WC, Chou TY, et al. Increased NBS1 expression is a marker of aggressive head and neck cancer and overexpression of NBS1 contributes to transformation. Clin Cancer Res. 2006;12:507–515
  18. Connell PP, Jayathilaka K, Haraf DJ, et al. Pilot study examining tumor expression of Rad51 and clinical outcomes in human head cancers. Int J Oncol. 2006;28:1113–1119
  19. Willers H, Taghian AG, Luo CM, et al. Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. Mol Cancer Res. 2009;7:1304–1309
  20. Collis SJ, Tighe A, Scott SD, et al. Ribozyme minigene-mediated Rad51 down-regulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Res. 2001;29:1534–1538
  21. Yu D, Sekine E, Fujimori A, et al. Downregulation of BRCA2 causes radio-sensitization of human tumor cells in vitro and in vivo. Cancer Sci. 2008;99:810–815
  22. Iliakis G, Wu WQ, Wang ML. DNA double strand break repair inhibition as a cause of heat radiosensitization: Re-evaluation considering backup pathways of NHEJ. Int J Hyperthermia. 2008;24:17–29
  23. Frankenberg-Schwager M, Gebauer A, Koppe C, et al. Single-Strand annealing, conservative homologous recombination, nonhomologous DNA end joining, and the cell cycle-dependent repair of DNA double-Strand breaks induced by sparsely or densely ionizing radiation. Radiat Res. 2009;171:265–273
  24. Camphausen K, Tofilon PJ. Inhibition of Hsp90: A multitarget approach to radiosensitization. Clin Cancer Res. 2007;13:4326–4330
  25. Noguchi M, Yu D, Hirayama R, et al. Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor seventeen-allylamino-seventeen-demethoxygeldanamycin. Biochem Biophys Res Commun. 2006;351:658–663
  26. Chen G, Yuan SSF, Liu W, et al. Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. J Biol Chem. 1999;274:12748–12752
  27. Russell JS, Brady K, Burgan WE, et al. Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res. 2003;63:7377–7383
  28. Bartkowiak D, Hipp PR, Mendonca MS, et al. A radioprotective effect of imatinib (Gleevec((R))) in human squamous carcinoma cells. Strahlenther Onkol. 2007;183:432–439
  29. Chinnaiyan P, Huang SM, Vallabhaneni G, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 2005;65:3328–3335
  30. Li LP, Wang H, Yang ES, et al. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res. 2008;68:9141–9146
  31. Prados MD, Chang SM, Butowski N, et al. Phase II Study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009;27:579–584
  32. Peereboom DM, Shepard DR, Ahluwalia MS, et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neuro Oncol. 2009;
  33. Brown PD, Krishnan S, Sarkaria JN, et al. Phase (I/II Trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group study N0177). J Clin Oncol. 2008;26:5603–5609
  34. McBride WH, Iwamoto KS, Syljuasen R, et al. The role of the ubiquitin/proteasome system in cellular responses to radiation. Oncogene. 2003;22:5755–5773
  35. Murakawa Y, Sonoda E, Barber LJ, et al. Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells. Cancer Res. 2007;67:8536–8543
  36. Shi W, Ma ZF, Willers H, et al. Disassembly of MDC1 foci is controlled by ubiquitin-proteasome-dependent degradation. J Biol Chem. 2008;283:31608–31616
  37. Berenson JR, Yellin O, Patel R, et al. A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res. 2009;15:1069–1075
  38. Brunner TB, Geiger M, Grabenbauer GG, et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol. 2008;26:2699–2706
  39. De Schutter H, Nuyts S. Radiosensitizing potential of epigenetic anticancer drugs. Anti Cancer Agents Med Chem. 2009;9:99–108
  40. Adimoolam S, Sirisawad M, Chen J, et al. HDAC inhibitor PCI-24781 decreases Rad51 expression and inhibits homologous recombination. Proc Natl Acad Sci U S A. 2007;104:19482–19487

 Supported in part by the ASTRO Resident in Radiation Oncology Research Seed Grant (CAB) and the National Cancer Institute and the Susan G. Komen Breast Cancer Research Foundation (SNP).

PII: S1053-4296(10)00035-4

doi: 10.1016/j.semradonc.2010.05.001

Seminars in Radiation Oncology
Volume 20, Issue 4 , Pages 267-273.e3 , October 2010

Article Tools

* Image Usage & Resolution